 Results Medical Research Council phase II study low dose cisplatin methotrexate primary treatment transitional cell carcinoma bladder series untreated patients category bladder cancer underwent treatment low dose methotrexate cisplatin patients eligible assessment response Complete response CR patients partial response overall response rate Treatment major morbidity treatment-related deaths median follow-up years survival rates patients recurrence-free definitive local therapy cystectomy radiotherapy follow-up months